SYM2267

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: SYM2267
• 英文别名: 1-(4-amino-phenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5H-2,3-benzodiazepine；1-[1-(4-Aminophenyl)-7-methoxy-4-methyl-4,5-dihydro-2,3-benzodiazepin-3-yl]ethanone
• 化学式: C₁₉H₂₁N₃O₂
• 分子量: 323.395
• InChiKey: XVGHLVHYOZFYNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-Acetyl-3.5-dihydro-4-methyl-7-methoxy-1-(4-nitrophenyl)-5H-2,3-benzodiazepine 在 钯 作用下， 以 乙醇 为溶剂， 生成 SYM2267
  参考文献：
  名称：

  5H-2,3-benzodiazepine antagonists of excitatory amino acid receptors

  摘要：

  提供了替代苯二氮平类化合物，其作为非NMDA离子型兴奋性氨基酸（EAA）受体拮抗剂具有活性。这些化合物通常是7-或8-单取代的5H-2,3-苯二氮平。这些化合物可用于治疗与非NMDA离子型EAA受体过度激活相关的疾病。此外，这些化合物还可用作测试剂，以识别和表征其他化合物用于治疗这些疾病。这些化合物在治疗上可用作镇静剂或用于治疗神经精神药理学疾病，如中风、缺血和癫痫。这些化合物可以与适当的载体组合用于口服或静脉注射。这些化合物可以口服或静脉注射用于治疗与非NMDA EEA受体功能相关的各种疾病。

  公开号：

  US20020025958A1

文献信息

• Methods and compositions for treating inflammatory disorders of the airways
  申请人：——

  公开号：US20040152694A1

  公开（公告）日：2004-08-05

  The present invention provides compositions and methods for treating inflammatory disorders of the airways by the administration of a therapeutically effective amount of a modulator according to the invention. More specifically, the invention relates to the treatment of airway inflammations including asthma or an asthma-related pathologies.

  本发明提供了通过施用治疗有效量的根据本发明的调节剂来治疗气道炎症性疾病的组合物和方法。更具体地说，本发明涉及气道炎症的治疗，包括哮喘或与哮喘相关的病症。
• 5H-2,3-BENZODIAZEPINE ANTAGONISTS OF EXCITATORY AMINO ACID RECEPTORS
  申请人：Annovis, Inc.

  公开号：EP1296960A2

  公开（公告）日：2003-04-02
• US6887867B2
  申请人：——

  公开号：US6887867B2

  公开（公告）日：2005-05-03
• [EN] 5H-2,3-BENZODIAZEPINE ANTAGONISTS OF EXCITATORY AMINO ACID RECEPTORS<br/>[FR] ANTAGONISTES 5H-2,3-BENZODIAZEPINE DE RECEPTEURS D'ACIDE AMINE EXCITATEURS
  申请人：ANNOVIS INC

  公开号：WO2001098280A2

  公开（公告）日：2001-12-27

  Substituted benzodiazepine compositions are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compounds are generally 7- or 8-mono substituted 5H-2,3-benzodiazepines. The compositions are useful for treating disorders associated with excessive activation of the non-NMDA subtype of the ionotropic EAA receptor. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The compounds are useful therapeutically as sedatives or for the treatment of neurosychopharmacological disorders such as stroke, ischemia and epilepsy. The compositions may be provided in combination with a suitable carrier for oral or parenteral administration. The compounds may be administered orally or parenterally for the treatment of a variety of disorders associated with non-NMDA EAA receptor function.
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：UNIV PAIS VASCO

  公开号：WO2011076946A2

  公开（公告）日：2011-06-30

  The invention relates to AMPA receptor inhibitors and NMDA receptor inhibitors for use in the treatment of a disease associated with deposition of amyloid proteins, more precisely, Alzheimer's disease.